Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that its shareholders have approved an increase in the number of authorized shares of common stock from 145 million to 290 million at the Annual Meeting of Stockholders held on May 11, 2011. The increase enables the Company to effect a two-for-one stock split, payable in the form of a 100 percent stock dividend, as approved by Alexion’s Board of Directors in March 2011 and announced at that time. The record date for the stock split is May 2, 2011. Stockholders will receive one additional share for every share they own as of the close of business on May 2, 2011. The additional shares are expected to be distributed after the close of business on May 20, 2011. Reporting of the Alexion share price on a split-adjusted basis will commence on May 23, 2011.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH, a debilitating, ultra-rare and life-threatening blood disorder. Soliris is approved in more than 35 countries. Alexion is evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.
Irving Adler, 203-271-8210
Senior Director, Corporate Communications and Public Policy
Makovsky & Company
Mark Marmur, 609-354-8135
Rhonda Chiger, 917-322-2569